Press releases
- Jacobio Pharma Announced its KRAS G12C inhibitor reached the primary endpoint
- Jacobio Pharma to Present Data of PARP7 Inhibitor and P53 Reactivator at the 2024 AACR Annual Meeting
- Jacobio Pharma Announces 2023 Annual Results
- Jacobio Pharma Receives IND Approval for P53 Y220C Activator JAB-30300 in the U.S.
- Jacobio Announces China CDE Clearance for Phase III Clinical Trial of SHP2 Inhibitor Plus KRAS G12C Inhibitor
More ▼
Key statistics
On Tuesday, Jacobio Pharmaceuticals Group Co Ltd (JBPHF:PKC) closed at 0.295, 0.00% above its 52-week low of 0.295, set on Feb 20, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.295 |
---|---|
High | 0.295 |
Low | 0.295 |
Bid | -- |
Offer | -- |
Previous close | 0.295 |
Average volume | -- |
---|---|
Shares outstanding | 791.76m |
Free float | 442.77m |
P/E (TTM) | -- |
Market cap | 1.55bn HKD |
EPS (TTM) | -0.5019 HKD |
Data delayed at least 15 minutes, as of Feb 20 2024 19:21 GMT.
More ▼